MET and breast cancer: Moreover, our results showed no difference in c-Met/PI3K/Akt pathway activation and IC50 values of crizotinib between the T24 and T24R2 cell lines under the 3D spheroid model, suggesting that crizotinib can suppress BC cell lines regardless of cisplatin sensitivity.